Medtronic (MDT) Receives Regulatory Approval For Endeavor Drug-Eluting Coronary Stent in Japan

FREE Breaking News Alerts from StreetInsider.com!

More News related to MDT

Medtronic (MDT) Commences 2 New Trials for Symplicity RDS Evaluation
Medtronic Launches Two New Clinical Programs to Evaluate the Use of Symplicity™1 Renal Denervation System across Multiple Conditions
Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2012
Medtronic Stent Resulted in 90% Freedom from Reinterventions in Narrowed Leg Arteries at 12 Months in International Study
2012 Economic Outlook - Report Highlights Red Hat, Inc. and Medtronic, Inc.

More News related to Corporate News

March 30, 2009 8:36 AM EDT

edtronic, Inc. (NYSE: MDT) announced approval of its Endeavor drug-eluting coronary stent system by the Japanese Ministry of Health, Labor and Welfare (MHLW), clearing the way for the highly anticipated launch of the product in the world's second largest market for advanced medical technology.

Medtronic plans to launch the Endeavor drug-eluting stent (DES) immediately following the authorization of reimbursement which is expected on May 1. Following the launch in Japan, the Endeavor DES will be commercially available for the treatment of coronary artery disease in every major market in the world. The Endeavor DES provides the reassurance of long-term safety and durable efficacy in the treatment of coronary artery disease.

Sign up at EasyStockAlerts for free to see your stock news before it breaks to the rest of the public!